File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Intraocular cytokines in neovascular age-related macular degeneration non-responder to ranibizumab treatment

TitleIntraocular cytokines in neovascular age-related macular degeneration non-responder to ranibizumab treatment
Authors
Issue Date2017
PublisherAssociation for Research in Vision and Ophthalmology. The Journal's web site is located at http://www.iovs.org
Citation
The Association for Research in Vision and Ophthalmology Annual Meeting, Baltimore, MD, 7-11 May 2017. In Investigative Ophthalmology & Visual Science, 2017, v. 58, p. 3205 How to Cite?
AbstractPurpose : To evaluate cytokines level in aqueous humor of ranibizumab (RN) non-responders with neovascular AMD (nAMD) who were treated with either combination of ranibizumab (RN), and photodynamic therapy (PDT) or aflibercept (AF) and explore the prediction cytokines for RN non-responders Methods : This prospective study collected aqueous specimen prospectively from RN non-responder receiving either AF or combination PDT (Study gr.) and RN responders patients (Control gr.) for cytokine analysis at baseline, month 1, 2 and 3 visit of treatment. Cytokines level and changes in 3 treatment groups were compared by using GLMM. Weighted propensity score was used to adjusted for covariate. VEGF, PDGF,PLGF and others angiogenesis/inflammatory cytokines were analyzed by Bio-Plex® Multiplex Immunoassays. Results : Eleven, 8 and 13 eyes received AF treatment, combined PDT, and control respectively. Mean change of visual acuity from baseline is improved [WC1] in the control gr. (P<0.05) while study gr. didn’t show significant changes. In PDT group, 75% of patients showed stabilization or improvement in AMD clinical activity while PLGF, PDGF and leptin level are significant increase at first month: At 2 months visit, VEGF-A level is increase while Endoglin and HB-EGF decline when compare to baseline. At 3 months visit, VEGF-C and HGF concentration are higher in AF group than control group (p=0.02 and 0.02). There are no different in PLGF,PDGF,VEGF-A levels between each treatment group in all visit. PLGF level was higher in study gr. while IL-7 was lower in study gr. (P=0.02 and 0.04 respectively). The combination level of Angiopoetin 2, IL-6, ICAM, Follistatin and IL-3 can predict the response of RN treatment with 83% sensitivity and 72% specificity. Conclusions : Switching to AF may not reduce major cytokines level but resulted in improvement of visual acuity. Combination of PDT and RN resulted increase angiogenesis cytokines. The lack of IL-7 was found in non-responder patient. Apart from cytokine levels, other factors such as cytokine receptors and immune system activity may play a role in non-response patient.
Persistent Identifierhttp://hdl.handle.net/10722/248283
ISSN
2023 Impact Factor: 5.0
2023 SCImago Journal Rankings: 1.422

 

DC FieldValueLanguage
dc.contributor.authorPongsachareonnont, P-
dc.contributor.authorLam, WC-
dc.contributor.authorMak, MYK-
dc.date.accessioned2017-10-18T08:40:46Z-
dc.date.available2017-10-18T08:40:46Z-
dc.date.issued2017-
dc.identifier.citationThe Association for Research in Vision and Ophthalmology Annual Meeting, Baltimore, MD, 7-11 May 2017. In Investigative Ophthalmology & Visual Science, 2017, v. 58, p. 3205-
dc.identifier.issn0146-0404-
dc.identifier.urihttp://hdl.handle.net/10722/248283-
dc.description.abstractPurpose : To evaluate cytokines level in aqueous humor of ranibizumab (RN) non-responders with neovascular AMD (nAMD) who were treated with either combination of ranibizumab (RN), and photodynamic therapy (PDT) or aflibercept (AF) and explore the prediction cytokines for RN non-responders Methods : This prospective study collected aqueous specimen prospectively from RN non-responder receiving either AF or combination PDT (Study gr.) and RN responders patients (Control gr.) for cytokine analysis at baseline, month 1, 2 and 3 visit of treatment. Cytokines level and changes in 3 treatment groups were compared by using GLMM. Weighted propensity score was used to adjusted for covariate. VEGF, PDGF,PLGF and others angiogenesis/inflammatory cytokines were analyzed by Bio-Plex® Multiplex Immunoassays. Results : Eleven, 8 and 13 eyes received AF treatment, combined PDT, and control respectively. Mean change of visual acuity from baseline is improved [WC1] in the control gr. (P<0.05) while study gr. didn’t show significant changes. In PDT group, 75% of patients showed stabilization or improvement in AMD clinical activity while PLGF, PDGF and leptin level are significant increase at first month: At 2 months visit, VEGF-A level is increase while Endoglin and HB-EGF decline when compare to baseline. At 3 months visit, VEGF-C and HGF concentration are higher in AF group than control group (p=0.02 and 0.02). There are no different in PLGF,PDGF,VEGF-A levels between each treatment group in all visit. PLGF level was higher in study gr. while IL-7 was lower in study gr. (P=0.02 and 0.04 respectively). The combination level of Angiopoetin 2, IL-6, ICAM, Follistatin and IL-3 can predict the response of RN treatment with 83% sensitivity and 72% specificity. Conclusions : Switching to AF may not reduce major cytokines level but resulted in improvement of visual acuity. Combination of PDT and RN resulted increase angiogenesis cytokines. The lack of IL-7 was found in non-responder patient. Apart from cytokine levels, other factors such as cytokine receptors and immune system activity may play a role in non-response patient.-
dc.languageeng-
dc.publisherAssociation for Research in Vision and Ophthalmology. The Journal's web site is located at http://www.iovs.org-
dc.relation.ispartofInvestigative Ophthalmology & Visual Science-
dc.titleIntraocular cytokines in neovascular age-related macular degeneration non-responder to ranibizumab treatment-
dc.typeConference_Paper-
dc.identifier.emailLam, WC: waichlam@hku.hk-
dc.identifier.authorityLam, WC=rp02162-
dc.identifier.hkuros281925-
dc.identifier.volume58-
dc.identifier.spage3205-
dc.identifier.epage3205-
dc.publisher.placeUnited States-
dc.identifier.issnl0146-0404-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats